BioNTech's malaria vaccine effort is based on its mRNA technology, which was employed during the pandemic to quickly develop COVID-19 vaccines, by prompting the human body to make a protein that ...

The World Health Organization (WHO) estimates that there were around 263 million malaria cases in 2023 and 597,000 deaths.

BioNTech SE has begun human trials on a vaccine for malaria, a fresh test for the messenger RNA technology that powered the most successful immunizations against Covid-19.. The first patient was ...

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for malaria prevention.

BioNTech has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on Friday. The Phase 1 trial is ...

BioNTech's pipeline also includes mRNA vaccines for influenza, malaria, and other infectious diseases, as well as BNT162, an individualized cancer immunotherapy that has shown promising results in ...

ANKARA. BioNTech, a company founded by Turkish German immigrants that is famed for its COVID-19 vaccine, announced on Friday that it has started clinical trials for a malaria vaccine.

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the ...

BERLIN — BioNTech on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said. We apologize, but this video has failed to load. Try ...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the ...